Company news

Mindset Pharma Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Mindset Pharma Announces Closing of Arrangement

October 27, 2023

Mindset Pharma Announces Receipt of Final Order

October 25, 2023

Mindset Pharma Announces Shareholder Approval of Arrangement

October 19, 2023

Mindset Pharma Provides Clarifying Disclosure in Connection with Proposed Plan of Arrangement

October 5, 2023

Mindset Pharma Announces Mailing of Circular and Receipt of Interim Order

September 22, 2023

Otsuka Pharmaceutical to Acquire Mindset Pharma

August 31, 2023

Mindset Pharma Receives Approval for Phase II Clinical Trial Evaluating MSP-1014 for the Treatment of Major Depressive Disorder

June 22, 2023

Mindset Pharma discusses decision to expand into non-hallucinogenic drug discovery

March 31, 2023

Mindset Pharma and PharmAla partnership makes first medical grade psilocybin sale in Australia

March 7, 2023

Mindset Pharma Announces Grant of Options

February 3, 2023

Mindset Pharma to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th

October 6, 2021

Mindset Announces Participation at Upcoming Events in June 2021

June 1, 2021

Mindset Pharma Invited to Present at Canaccord Genuity 41st Annual Growth Conference

May 5, 2021

Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds

April 29, 2021

Mindset Pharma Engages KCSA Strategic Communications to Provide Investor Relations Services

April 28, 2021

Mindset Pharma Invited to Present at H.C. Wainwright "Psychedelics in Psychiatry and Beyond" Virtual Conference

April 26, 2021

Mindset Pharma Announces Strong Confirmation of In Vivo Proof-of-Concept Across Its Entire New Drug Program Portfolio

April 20, 2021

Mindset Pharma Announces Exercise of Over-Allotment Option for Additional Gross Proceeds of $1.052 Million

April 19, 2021

Mindset Pharma Announces Closing of $7.5 Million Bought Deal Public Offering

April 15, 2021

Mindset Pharma Announces Filing of Amended and Restated FS and MD&A for the Three and Six Month Period Ended December 31, 2020

April 1, 2021

Mindset Pharma Expands Scientific Team: Dr. Malik Slassi Appointed Senior VP Innovation and Ian Dean Appointed Director Preclinical Development

March 30, 2021

Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform ("Cope"); Cope Expected to Be World's First in Vivo Psychedelic Benchmark Data Set

March 23, 2021

Mindset Pharma Announces Upsize of Bought Deal to $7.5 Million

March 22, 2021

Mindset Pharma Announces $5 Million Bought Deal Financing

March 22, 2021

Mindset Pharma Announces DTC Eligibility for OTCQB(R) Venture Listing

March 17, 2021

Mindset Pharma Files a Sixth U.S. Provisional Patent, Further Expanding Its Psychedelic Drug Candidates Pipeline With Novel DMT & 5-MeO-DMT Analogs

March 15, 2021

Mindset Pharma to Present at the Stifel GMP Conference - Psychedelics: Addressing the Global Mental Health Crisis

March 10, 2021

Mindset Pharma Appoints Leading Molecular Pharmacologist & Formulation Expert Dr. Joseph Gabriele to Scientific Advisory Board

March 8, 2021

Mindset Pharma Reaches Agreement to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis Process

February 22, 2021

Mindset Pharma Added to North American Psychedelics Index

February 19, 2021

Mindset Pharma Announces U.S. Listing Application for OTCQB Venture Market

February 17, 2021

Mindset Announces Milestone in New Drug Program with Successful Proof-of-Concept Animal Studies of Its Patent-Pending Psilocybin-Inspired Drug Candidates

February 10, 2021

Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds

February 5, 2021

Mindset Pharma Retains Corporate Development Advisors

February 1, 2021

Mindset Selects Compounds from Its Third Psilocybin-Inspired Drug Family to Move into in vivo PoC Studies

February 1, 2021

Mindset Pharma Announces Listing on the Frankfurt Stock Exchange

January 27, 2021

Mindset Pharma to Present at Inaugural KCSA Psychedelic Investor Conference

January 20, 2021

Mindset Pharma Invited to Present at Upcoming Canaccord Genuity Mental Health Conference

January 14, 2021

Mindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of Potential Clinical Use Cases Including Micro-Dosing

January 6, 2021

Mindset Engages Hybrid Financial Inc.

December 31, 2020

Mindset Further Expands Portfolio of Psychedelic Drug Candidates with Third U.S. Provisional Patent Application; 50 Total New Psychedelic Patent-Pending Compounds Synthesized

December 29, 2020